a phase i study of the novottf-200m and novo ttf-200a systems for the treatment of refractory spinal metastasis

Conditions: Spinal Metastasis

Summary: this clinical research study is to learn about the safety of the novottf-200m and novo ttf-200a systems, when used either alone or in combination with standard therapy, in patients with tumors that did not respond to treatment.

primary objective: to evaluate the safety of applying ttfields at frequencies between 150 and 200khz, using the ttf200m and ttf-200a systems (respectively), alone or in combination with available systemic therapies as adjuvant treatment in patients with radiation refractory spinal metastasis. safety will be specifically assessed based on absence of wound dehiscence in the surgical group and severe cellulitis requiring drainage and intravenous antibiotics in both surgical and non-surgical cohorts. secondary objective: to assess local spine progression-free survivals at about every 3 months (+/- 1 month) in these patients until one of the following occurs: local disease progression, transition to hospice, loss of follow up, withdrawal from study or consent, whichever comes first. exploratory objectives: 1. to evaluate the safety of application of tumor treating fields at frequencies between 150khz and 200 khz using the ttf-200m and ttf-200a systems (respectively), alone or in combination with available systemic therapy as adjuvant treatment after surgery for spinal cord decompression in patients with refractory spinal metastasis 2. to assess local spine progression-free survivals at about every 3 months (+/- 1 month) until their local disease progresses, they go to hospice, or are off study, whichever is earlier, in patients in 2.3(a). 3. to evaluate the safety of application of tumor treating fields at frequencies between 150khz and 200 khz using the ttf-200m and ttf-200a systems (respectively), alone or in combination with available systemic therapy as adjuvant treatment for patients with radiation refractory spinal metastasis who are unable to undergo surgery due to high risk of complications. 4. to assess local spine progression-free survivals at about every 3 months (+/- 1 month) until their local disease progresses, they go to hospice, or are off study, whichever is earlier, in patients in 2.3(c). 5. to evaluate change in plasma ctdna levels before initiation (baseline) to cycle 1 and 3.

Eligibility criteria:
inclusion criteria: 1. patients with one or more spinal metastasis(es) affecting levels between c1 to s4 which have been previously treated with surgery and/or maximal doses radiation therapy to the spinal metastasis. for patients in the surgical group, patients must have completed maximal intralesional debulking of their tumor (within 60 days). 2. no more radiation options available for treatment to the spinal metastasis(es) that will undergo the ttf treatment 3. male or female subjects aged ≥ 18 years. 4. women of child-bearing potential (women who are not postmenopausal for at least one year or are not surgically sterile) must agree prior to study entry to use adequate contraception (e.g., hormonal, barrier device, or abstinence) for the duration of study participation. 5. patients must have a karnofsky performance scale (kps) (appendix d) score of at least 70%. 6. patients must have the ability to independently disconnect the arrays or turn off the system if they feel uncomfortably hot while using the device. 7. patients (and/or legally authorized representative) should be able to fully understand the requirements of the trial, including the need to use the device for at least 18 hours per day, be willing to comply with all trial visits and assessments and be willing and able to sign an institutional review board (irb) approved written informed consent document (or provide assent where applicable). 8. patients with the following tumor histologies (numbers in parenthesis represent the frequencies/device patients with these histologies will be treated with): 1. non-small cell lung cancer (150khz, ttf-200m) 2. chordoma (150khz, ttf-200m) 3. breast adenocarcinoma (150hkz, ttf-200m) 4. liver/gastrointestinal malignancy (150 khz, ttf-200m) 5. endocrine origin carcinoma (150khz, ttf-200m) 6. renal cell carcinoma (200khz, ttf-200a) 7. prostate adenocarcinoma (200khz, ttf-200a) 8. sarcoma (200khz, ttf-200a) 9. for the non-surgical group only, expected survival of more than 8 months as confirmed by the primary oncologist. 10. for the non-surgical group only, in case of multiple noncontiguous vertebral levels requiring treatment, all sites must be included under the largest length of the antero-posterior set of transducer arrays (25cm). exclusion criteria: 1. psychiatric illness/social situations (homeless or living in a foreign country) that would limit compliance with study requirements. 2. physical or cognitive limitation that prevents the ability to independently disconnect the arrays or turn off the system if they feel uncomfortably hot while using the device. this includes patients that need a legally authorized representative for consent. 3. patients in the surgery group who have not fully recovered from the spinal surgery, where wound healing is compromised, requiring healing by second intention (i.e., the wound is left open and heals spontaneously). 4. history of allergic reactions or sensitivity to conductive hydrogels used on electrocardiogram (ecg) stickers or transcutaneous electrical nerve stimulation (tens) electrodes. 5. implanted pacemaker, defibrillator, nerve stimulator or other active electronic medical devices in the area of surgery or application of the skin transducers. 6. women who are pregnant or lactating. 7. prior surgery to the spinal level(s) to be treated with ttf is not an exclusion criterion. 8. enrollment on another clinical trial with investigational drugs/devices is not an exclusion criterion and is kept at the discretion of the treating surgeon. 9. patients with leptomeningeal disease. 10. patients with severe pre-existing dermatological conditions (i.e., active herpes zoster, bullous pemphigoid reactions, stevens-johnson syndrome) that might interfere with interpretation of the device's skin toxicity. 11. patients receiving targeted therapy (i.e., egfr inhibitors) who present with severe dermatological reactions at the site(s) to receive treatment with novottf-200a or novottf-200m. prior treatment and complete resolution of a prior severe dermatological reaction are not exclusion criteria. 12. multiple noncontiguous progressive spine tumors separated by more than 25 cm.